Paragon Bioservices Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Paragon Bioservices's estimated annual revenue is currently $24.3M per year.(i)
  • Paragon Bioservices received $5.0M in venture funding in August 2018.
  • Paragon Bioservices's estimated revenue per employee is $155,000
  • Paragon Bioservices's total funding is $20M.

Employee Data

  • Paragon Bioservices has 157 Employees.(i)
  • Paragon Bioservices grew their employee count by -21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon's aim is to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Paragon Bioservices News

2014-10-28 - Paragon Bioservices Raises $13M in Series A Financing

Paragon Bioservices, Inc., a Baltimore, MD-based contract research and manufacturing organization that aims to accelerate the development and manufacturing of biopharmaceuticals and vaccines, raised $13m in Series A financing. The round was led by NewSpring Capital and Camden Partners. In conju ...

2014-11-04 - Paragon Bioservices raises $13M to expand CRO/CMO work in vaccines, biologics

The company also just brought on a new COO, Pete Buzy, to its leadership team. The guy was formerly CFO of Martek Biosciences for 13 years, and helped orchestrate its $1.1 billion sale to Royal DSM. “Market factors, including the consolidation of the pharmaceutical industry and the growth of vi ...

2018-01-25 - Paragon Bioservices Bolsters Leadership Ranks with Executive Appointments

Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces today the promotion of key personnel and the addition of two industry veterans to its leadersh ...

09/07/2019 - Viral vector and plasmid market set for rapid growth

Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...

09/08/2019 - Catalent's legacy business outshined by acquisitions

By April of 2019, Catalent had agreed to a $1.2 billion acquisition of gene therapy developer Paragon Bioservices. And most recently, the ...

04/26/2019 - Why Paragon Bioservices' $1.2B acquisition deal matters to ...

Why Paragon Bioservices' $1.2B acquisition deal matters to Baltimore ... it had agreed to acquire Paragon Bioservices in a $1.2 billion deal.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Paragon Bioservices Funding

DateAmountRoundLead InvestorsReference
2014-10-29$13.0MUndisclosedNewSpring CapitalArticle